Asahi Kasei Completes Acquisition of Aicuris

Asahi Kasei has completed its previously announced acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company, accelerating its efforts to build a global specialty pharmaceutical platform by expanding further into severe infectious diseases.

“The completion of the Aicuris acquisition reflects the deliberate execution of our pharmaceutical strategy and strengthens our position in infectious diseases, a core area where we see sustained demand, high unmet need, and long-term growth,” said Ken Shinomiya, Head of Asahi Kasei’s Healthcare Sector. “Aicuris adds a differentiated portfolio and scientific capabilities that enhance the quality of our pipeline, while also providing a near-term commercial opportunity. By integrating Aicuris into our global development and commercialization platform, we are further scaling our specialty pharmaceutical business.”

Aicuris adds three antiviral assets spanning marketed and clinical-stage development, complementing Asahi Kasei’s existing treatment portfolio: Prevymis, pritelivir, and AIC468. These assets address growing market opportunities across transplant and infectious disease environments.

Asahi Kasei plans to advance Aicuris’s portfolio through its U.S. subsidiary, Veloxis Pharmaceuticals, Inc., a leader in transplant medicine.

“We see strong strategic alignment between Veloxis and Aicuris under the Asahi Kasei pharmaceutical strategy,” said Stacy Wheeler, CEO, Veloxis. “Aicuris’s infectious disease experience, together with Veloxis’s established transplant-focused research and commercialization capabilities, provides a solid foundation to support development efforts that address areas of unmet need among immunocompromised patients.”

Asahi Kasei expects the acquisition to contribute positively to operating income after amortization of goodwill and other intangible assets from fiscal 2028 onward.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.